Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been given an average recommendation of “Moderate Buy” by the eleven analysts that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $101.8571.

LNTH has been the subject of a number of research analyst reports. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $94.00 target price on shares of Lantheus in a research report on Thursday, May 7th. William Blair reaffirmed an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. Mizuho boosted their price target on shares of Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Finally, Jefferies Financial Group restated a “buy” rating and set a $110.00 price target on shares of Lantheus in a research note on Tuesday, March 17th.

Lantheus Stock Up 0.7%

Lantheus stock opened at $109.80 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. Lantheus has a 52-week low of $47.25 and a 52-week high of $111.46. The firm has a 50 day moving average price of $95.88 and a two-hundred day moving average price of $79.87. The firm has a market cap of $7.15 billion, a price-to-earnings ratio of 26.46 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.21. The firm had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period last year, the company posted $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts predict that Lantheus will post 4.49 EPS for the current year.

Institutional Trading of Lantheus

A number of hedge funds and other institutional investors have recently bought and sold shares of LNTH. Vanguard Group Inc. increased its holdings in Lantheus by 1.7% during the 3rd quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after purchasing an additional 115,338 shares in the last quarter. M&T Bank Corp bought a new stake in Lantheus during the 4th quarter worth approximately $370,950,000. Farallon Capital Management LLC increased its holdings in Lantheus by 56.1% during the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after purchasing an additional 1,950,252 shares in the last quarter. Reinhart Partners LLC. increased its holdings in Lantheus by 15.9% during the 4th quarter. Reinhart Partners LLC. now owns 1,562,576 shares of the medical equipment provider’s stock worth $103,990,000 after purchasing an additional 214,820 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Lantheus by 3.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock worth $94,202,000 after purchasing an additional 44,374 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.